logo image
search icon
Non-muscle Invasive Bladder Cancer Market

Non-muscle Invasive Bladder Cancer Market Size, Share & Trends Analysis Report By Treatment Type (Immunotherapy, Chemotherapy, Targeted Therapy), By Cancer Type (Low Grade Bladder Cancer, High Grade Bladder Cancer), By End-user (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031

Report ID : 2859 | Published : 2024-10-17 | Pages: 170 | Format: PDF/EXCEL

The Non-muscle Invasive Bladder Cancer Market Size is valued at USD 2.7 billion in 2023 and is predicted to reach USD 10.9 billion by the year 2031 at a 19.2% CAGR during the forecast period for 2024-2031.

non-muscle invasive

A form of bladder cancer that is restricted to the innermost membrane of the bladder is Non-Muscle-Invasive Bladder Cancer (NMIBC), also known as superficial bladder cancer. NMIBC does not infiltrate deeper layers or adjacent tissues, unlike muscle-invasive bladder cancer, which permeates the muscle layer of the bladder wall. In contrast, it remains within the lining. The primary subtypes of NMIBC are carcinoma in situ (CIS), papillary tumors, and Ta/T1 tumors. CIS denotes high-grade, flat lesions that are restricted to the mucosal surface, whereas papillary tumors develop as tiny, finger-like projections on the interior bladder membrane. Ta tumors are restricted to the innermost layer of the bladder lining, whereas T1 tumors have infiltrated the connective tissue immediately beneath the lining but have not yet reached the muscle layer. This form of bladder cancer is a chronic condition that necessitates periodic surveillance and vigilant monitoring due to its tendency to recur despite treatment. Nevertheless, it typically has a more favorable prognosis than muscle-invasive bladder cancer.

Nevertheless, the identification of the patient population with specific mutations for targeted therapy regimens will be a significant impediment to the growth of the non-muscle invasive bladder cancer market. This is not a feasible option for all patients, as the costs of identification would be prohibitively high for payers, which would restrict the use of these drugs. Additionally, the market for non-muscle invasive bladder cancer is expected to witness significant expansion as the prevalence of the disease increases and new branded therapeutics with diverse mechanisms of action are introduced and adopted.

Competitive Landscape

Some Major Key Players In The Non-muscle Invasive Bladder Cancer Market:

  • TARIS Biomedical LLC
  • Merck & Co., Inc.
  • Herantis Pharma Oyj
  • Viventia Bio Inc.
  • Telormedix SA
  • Ferring B.V.
  • Altor BioScience Corporation
  • Novartis AG
  • Pfizer Inc.
  • GSK plc
  • Sanofi S.A.
  • Eli Lilly and Company
  • AstraZeneca
  • UroGen Pharma
  • Johnson & Johnson
  • CG Oncology
  • ImmunityBio
  • Theralase Technologies
  • Protara Therapeutics
  • enGene
  • Celgene Corporation
  • Hoffmann-La Roche Ltd
  • Other Market Players

Market Segmentation:

The Non-muscle Invasive Bladder Cancer market is categorized on the basis of Treatment Type, Cancer Type and End-user. The Treatment Type segment includes Immunotherapy, Chemotherapy, and Targeted Therapy. By Cancer Type, the market is segmented into Low Grade Bladder Cancer, and High-Grade Bladder Cancer. By End-user, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Based On Treatment Type, The Chemotherapy Segment Is Accounted As A Major Contributor In The Non-Muscle Invasive Bladder Cancer Market

The Chemotherapy category is expected to hold a major share in the global Non-muscle Invasive Bladder Cancer market in 2023. During chemotherapy, medications are administered in order to either kill cancer cells or halt the development of cancer cells. More tailored treatment choices are being made available to patients with bladder cancer as a result of recent developments, such as the creation of new chemotherapeutic drugs and the use of combination treatments, which aim to increase effectiveness while simultaneously reducing toxicity.

Hospital Pharmacies Segment Witness Growth At A Rapid Rate

The Hospital Pharmacies segment is calculated to grow at a rapid rate in the global Non-muscle Invasive Bladder Cancer market. Surgical procedures, chemotherapy, and radiation therapy are some of the comprehensive care services that are offered by hospitals, who are the major caregivers for the diagnosis and treatment of bladder cancer. Recent developments in the field of medicine include the use of Less intrusive surgical methods, the formation of multidisciplinary care teams, and the incorporation of modern imaging technology for the purpose of precise staging and treatment planning.

In The Region, The North America Non-Muscle Invasive Bladder Cancer Market Holds Significant Revenue Share.

The bladder cancer market in North America is seeing a number of developments, one of which is an increased emphasis on personalized care. This involves the use of genetic profiling and biomarker-driven medicines in order to modify treatment methods. The implementation of value-based care models, the implementation of healthcare reform measures, and the investment in novel technology to detect and treat bladder cancer are also being prioritized. As an additional point of interest, the market for bladder cancer is experiencing a number of trends in the Asia-Pacific region. These trends include increased knowledge about cancer prevention and early diagnosis, as well as rising healthcare expenditures and improvements in access to healthcare services. Additionally, there is a rising need for novel medicines and sophisticated treatment modalities, which is pushing investments in healthcare infrastructure and promoting cooperation between the public and private sectors in order to solve medical requirements that are not currently being fulfilled.

Recent Developments:

  • In April 2024, The FDA has granted approval for the use of the immunotherapy-enhancing medication N-803, also known as Anktiva, in conjunction with the immunotherapy Bacillus Calmette-Guerin (BCG), for the treatment of patients with non-muscle-invasive bladder cancer which is unresponsive to BCG.

Non-muscle Invasive Bladder Cancer Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 2.7 Bn

Revenue Forecast In 2031

USD 10.9 Bn

Growth Rate CAGR

CAGR of 19.2% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Treatment Type, Cancer Type and End-user.

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

TARIS Biomedical LLC, Merck & Co., Inc., Herantis Pharma Oyj, Viventia Bio Inc., Telormedix SA, Ferring B.V., Altor BioScience Corporation, Novartis AG, Pfizer Inc., GSK plc, Sanofi S.A., Eli Lilly and Company, and AstraZeneca, UroGen Pharma, Johnson & Johnson, CG Oncology, ImmunityBio, Theralase Technologies, Protara Therapeutics, enGene, Celgene Corporation, F. Hoffmann-La Roche Ltd

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Non-muscle Invasive Bladder Cancer Market Snapshot

Chapter 4.          Global Non-muscle Invasive Bladder Cancer Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Trends

4.5.        Investment and Funding Analysis

4.6.        Industry Analysis – Porter’s Five Forces Analysis

4.7.        Competitive Landscape & Market Share Analysis

4.8.        Impact of Covid-19 Analysis

Chapter 5.          Market Segmentation 1: By Treatment Type Estimates & Trend Analysis

5.1.        By Treatment Type & Market Share, 2023 & 2031

5.2.        Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Treatment Type:

5.2.1.    Immunotherapy

5.2.2.    Chemotherapy

5.2.3.    Targeted Therapy

Chapter 6.          Market Segmentation 2: By Cancer Type Estimates & Trend Analysis

6.1.        By Cancer Type & Market Share, 2023 & 2031

6.2.        Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Cancer Type:

6.2.1.    Low Grade Bladder Cancer

6.2.2.    High Grade Bladder Cancer

Chapter 7.          Market Segmentation 3: By End-User Estimates & Trend Analysis

7.1.        By End-User & Market Share, 2023 & 2031

7.2.        Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By End-User:

7.2.1.    Hospital Pharmacies

7.2.2.    Retail Pharmacies

7.2.3.    Online Pharmacies

Chapter 8.          Non-muscle Invasive Bladder Cancer Market Segmentation 4: Regional Estimates & Trend Analysis

8.1.        North America

8.1.1.    North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031

8.1.2.    North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031

8.1.3.    North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031

8.1.4.    North America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.2.        Europe

8.2.1.    Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031

8.2.2.    Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031

8.2.3.    Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031

8.2.4.    Europe Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.3.        Asia Pacific

8.3.1.    Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031

8.3.2.    Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031

8.3.3.    Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031

8.3.4.    Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.4.        Latin America

8.4.1.    Asia Pacific Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031

8.4.2.    Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031

8.4.3.    Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031

8.4.4.    Latin America Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.5.        Middle East & Africa

8.5.1.    Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2024-2031

8.5.2.    Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031

8.5.3.    Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031

8.5.4.    Middle East & Africa Non-muscle Invasive Bladder Cancer Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 9.          Competitive Landscape

9.1.        Major Mergers and Acquisitions/Strategic Alliances

9.2.        Company Profiles

 

9.2.1.    TARIS Biomedical LLC

9.2.2.    Merck & Co., Inc.

9.2.3.    Herantis Pharma Oyj

9.2.4.    Viventia Bio Inc.

9.2.5.    Telormedix SA

9.2.6.    Ferring B.V.

9.2.7.    Altor BioScience Corporation

9.2.8.    Novartis AG

9.2.9.    Pfizer Inc.

9.2.10.  GSK plc

9.2.11.  Sanofi S.A.

9.2.12.  Eli Lilly and Company

9.2.13.  AstraZeneca

9.2.14.  UroGen Pharma

9.2.15.  Johnson & Johnson

9.2.16.  CG Oncology

9.2.17.  ImmunityBio

9.2.18.  Theralase Technologies

9.2.19.  Protara Therapeutics

9.2.20.  enGene

9.2.21.  Celgene Corporation

9.2.22.  F. Hoffmann-La Roche Ltd

9.2.23.  Other Prominent Players

Segmentation of Non-muscle Invasive Bladder Cancer Market-

Non-muscle Invasive Bladder Cancer Market By Treatment Type -

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy

non-muscle invasive

Non-muscle Invasive Bladder Cancer Market By Cancer Type -

  • Low Grade Bladder Cancer
  • High Grade Bladder Cancer

Non-muscle Invasive Bladder Cancer Market By End-user-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Non-muscle Invasive Bladder Cancer Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Non-muscle Invasive Bladder Cancer Market Size?

The Non-muscle Invasive Bladder Cancer Market is expected to grow at a 19.2% CAGR during the forecast period for 2024-2031.

TARIS Biomedical LLC, Merck & Co., Inc., Herantis Pharma Oyj, Viventia Bio Inc., Telormedix SA, Ferring B.V., Altor BioScience Corporation, Novartis A

The Treatment Type, Cancer Type and End-user are three key segments of the Non-muscle Invasive Bladder Cancer Market.

North American region is leading the Non-muscle Invasive Bladder Cancer Market.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach